Log In
Monday 24th October 2016

New medicines could be hit by credit crunch

27th October 2008

Experts have said the credit crunch could affect the development of new types of medicine and treatment.

Professor David Wield, of the government-backed Economic and Social Research Council, said: "Venture capital is very important to biotech firms. It is often the main source of funding in the early stages of development and, without this, biotech firms will struggle to get their projects off the ground."


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2016